3SBio enters licensing deal for antibody-drug conjugate ALT-P7
12 October 2015 | By Victoria White
Preclinical proof-of-concept has demonstrated superiority of ALT-P7 over current drugs in murine models of HER2-positive breast cancer...
List view / Grid view
News
Lilly announces New York R&D site expansion
12 October 2015 | By Victoria White
Lilly has announced plans to add 30,000 square feet to its research and development site at the Alexandria Centre for Life Science in New York...
Eyevensys completes €7.5m Series A financing to develop EYS606
9 October 2015 | By Victoria White
The Company is developing EYS606, an innovative combination product associating a DNA plasmid encoding a therapeutic protein with an injection-electroporation device, for the treatment of Non-Infectious Posterior Uveitis...
Scientists use nano-diamonds to light up tumours
9 October 2015 | By Victoria White
The nano-diamonds could be used to identify cancerous tumours before they become life-threatening...
Nav1.5 identified as potential therapeutic target for breast cancer
9 October 2015 | By Victoria White
When using the shRNA in breast cancer cells, Nav1.5 levels were 'knocked down', resulting in reduced tumour growth rates and metastasis...
Gene therapy prevents disease effects in Parkinson’s disease model
9 October 2015 | By Victoria White
Researchers reported that treatment with IFNβ-gene therapy successfully prevented neuronal death and disease effects in an experimental model of the disease...
Researchers turn stem cells into mini-kidneys
8 October 2015 | By Victoria White
The breakthrough could allow the use of mini-organs to screen drugs either for the treatment of kidney disease or to find out if a new drug is likely to injure the kidney...
Acceleran presents preclinical data for muscle therapeutics ACE-083 and ACE-2494
8 October 2015 | By Victoria White
Acceleron reported the results at the 20th International Annual Congress of the World Muscle Society (WMS)...
Two-hit approach shows promise in breast cancer study
8 October 2015 | By Victoria White
Researchers have eradicated a specific type of breast cancer tumour in mice by disabling a cancer-causing pathway and administering an immune-molecule based mop-up therapy...
Nektar submits IND for NKTR-214 to treat solid tumours
8 October 2015 | By Victoria White
NKTR-214 is a CD122-biased immune-stimulatory cytokine that is designed to stimulate the expansion and maintenance of CD8-positive effector T-cells...
Cancer Research UK invests £15m to develop new cancer treatments
7 October 2015 | By Victoria White
The Cancer Research UK Centres Network Accelerator Award provides infrastructure support to research centres in order to encourage collaboration between different organisations and boost ‘bench to bedside’ science...
C4XD provides a research update on its IL-17 targeting leads
7 October 2015 | By Victoria White
C4XD’s most advanced compound, an oral Orexin-1 antagonist for the treatment of addiction, is in formal preclinical safety and toxicity studies...
Cell Therapy Catapult launches the Cell History File
7 October 2015 | By Victoria White
The Cell History File has been designed to fulfil the role of a ‘cell passport’ that can accompany a tissue or cell derived product as it progresses through various processing stages...
Global and USA Biosimilar Market: Latest updates from Hospira, Sandoz, Merck, Teva, Boehringer Ingelheim
7 October 2015 | By SMi Group
Leading organizations in the Biosimilars Development sector will meet at Biosimilars and Biobetters USA 2015 – the must-attend premier industry event which will take place in Iselin this November...
Horizon Discovery Group in-licenses oncology programme from Servier
7 October 2015 | By Victoria White
Horizon Discovery Group has in-licensed novel kinase inhibitors from Servier that exhibit great promise based on preclinical data for treatment of a range of cancer types...